Purpose of review Pathogenesis of interstitial lung diseases (ILD) has largely been investigated in the context of the most frequent ILD, idiopathic pulmonary fibrosis (IPF). We review studies of epithelial-to-mesenchymal transition (EMT) and discuss its potential contribution to collagen-producing (myo)fibroblasts in IPF.
INTRODUCTION
Interstitial lung diseases (ILD) refer to a collection of disorders characterized by varying degrees of inflammation and fibrosis in the lung interstitium. The cause of ILD is sometimes known (e.g., environmental factors, drugs, collagen vascular disease, and sarcoidosis). When the cause is unknown, it is labeled as idiopathic and further classified into the currently recognized single disease entities [1] . Research on pathogenesis has been conducted mostly in the context of the most frequent idiopathic ILD, idiopathic pulmonary fibrosis (IPF). In the currently accepted paradigm, a major factor in IPF pathogenesis is thought to be recurrent alveolar epithelial cell (AEC) injury [2
&&
,3]. Initial injury leads to aberrant activation of AECs, creating a profibrotic environment with accumulation of collagen-producing fibroblasts and myofibroblasts. To date, (myo)fibroblasts have been suggested to accumulate via three mechanisms: proliferation and differentiation of resident lung fibroblasts; epithelial-to-mesenchymal transition (EMT), in which AECs undergo transition to (myo)fibroblasts; and transition of bone marrow-derived fibrocytes or circulating progenitors to fibroblasts [4] . The significance and relative contribution of each pathway to fibrosis have not been definitively established, hampering development of novel therapies. We first review the latest advances on causes and underlying mechanisms of EMT and then focus on the ongoing controversy of whether and how EMT contributes to lung fibrosis and whether inhibition of EMT would be of benefit therapeutically.
Historically, disruption of cell contacts, hypoxia and inflammation have been proposed as potential triggers of EMT [5 && ]. In recent years, progress has been made in understanding the relationship between endoplasmic reticulum (ER) stress and IPF [6 && ]. The ER is an organelle in which secreted and membrane proteins fold and mature, and ER stress refers to activation of signaling pathways in response to relative insufficiency in protein folding capacity [7] . In the lung, mutations in genes encoding surfactant proteins SP-A2 and SP-C are associated with ILDs [8- 10, 11 & ], and ER stress due to mutant protein accumulation has been the proposed underlying mechanism leading to apoptosis and fibrosis [12, 13] . Recently ] found that integrin a3b1 is required for TGFb1-mediated Src kinase activation, which in turn activates b-catenin. In addition, they used a small molecule tankyrase inhibitor to increase expression of axin1, a negative regulator of Wnt/b-catenin signaling. Administration beginning 10 days after bleomycin instillation improved survival, attenuated fibrosis and lowered expression of a-SMA and collagen I, suggestive of a possible novel therapy. These articles point to the importance of the b-catenin-dependent signaling pathway in mediating TGFb-dependent effects in EMT/ fibrosis.
Other articles have investigated the role of Smad3 in relation to other pathways. Aoyagi-Ikeda et al. [37 & ] showed that activation of the Notch pathway induces EMT in vitro, perhaps through phosphorylation of Smad3, and a TGFb receptor kinase inhibitor suppressed Notch-induced a-SMA expression. Van der Velden and colleagues followed up their previous studies linking c-Jun N-terminal kinase 1 (JNK1) and TGFb in lung fibrosis and EMT [38, 39] . They showed that JNK1 directly interacts with Smad3 to phosphorylate the linker region, which enhances interactions between Smad3 and Smad4 and activates canonical TGFb signaling [40 & ]. Two groups have pursued the role of ezrin/ radixin/moesin (ERM) proteins in the rearrangement of actin filaments, which leads to changes in cell morphology, adhesion and migration in EMT. Haynes et al. [41 & ] showed in mammary epithelial cells that expression of moesin increases during TGFb-induced EMT, colocalizing with F-actin at cell protrusions. This increased expression led to morphological changes and actin filament remodeling. The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily of cell surface receptors.
Expression of RAGE is high in the lung compared with other organs, and it has been suggested to have a protective role in lung fibrosis [42, 43] 
DOES EPITHELIAL-TO-MESENCHYMAL TRANSITION CONTRIBUTE TO LUNG FIBROSIS IN VIVO?
We now turn to the controversy surrounding EMT in the context of lung fibrosis.
Evidence for epithelial-to-mesenchymal transition
There are two main reasons that EMT is considered to contribute to pulmonary fibrosis: results of lineage tracing studies in mouse models, and co-expression of epithelial and mesenchymal markers in human lung samples with histologic manifestations of usual interstitial pneumonia (UIP), the pathologic correlate of IPF. Lineage tracing is a strategy used to identify progeny of a specific cell or a group of cells by permanently tagging them to express a reporter gene [49 & ]. To show EMT, an enzyme with recombination capacity, usually Cre recombinase, is expressed in one mouse under control of a promoter that drives expression specifically in alveolar epithelium. When these mice are crossed with reporter mice, Cre activates expression of the reporter gene, usually green fluorescent protein (GFP) or b-galactosidase (b-gal), in cells originating from alveolar epithelium. To date, there have been seven lineage tracing studies evaluating the contribution of EMT to pulmonary fibrosis, with six in support of EMT (Table 1) ], using the SP-C promoter to express Cre, labeled lung AECs with b-gal. After administration of bleomycin, confocal microscopy revealed that deletion of TGFb receptor 2 in lung epithelium resulted in fewer fibroblasts expressing b-gal and S100 calcium binding protein A4 (S100A4, also known as fibroblastspecific protein 1, or FSP1). However, a-SMA expression, a marker for myofibroblasts, was rarely seen in EMT-derived cells expressing b-gal, suggestive of EMT but not further transition to myofibroblasts. DeMaio et al. [17 && ] utilized the Nkx2.1 promoter to generate mice in which AECs express GFP. Twentyone days after administration of bleomycin, they colocalized GFP with mesenchymal markers collagen I, vimentin and a-SMA by confocal microscopy. Vimentin and a-SMA were expressed in approximately 4% of AEC-derived cells identified by fluorescence-activated cell sorting (FACS) analysis of GFP-expressing cells. These two recent studies reinforced previous lineage tracing studies indicating that EMT contributes to the pathogenesis of pulmonary fibrosis in vivo, at least in the bleomycin model.
Human IPF studies also support the significance of EMT in pulmonary fibrosis. Immunohistochemistry has revealed colocalization of epithelial and mesenchymal markers in the fibrotic lung [28, 50, 54] . Recently, Marmai et al. [55 && ], in addition to immunohistochemistry, performed laser capture microdissection to isolate RNA from epithelial cells in the IPF lung. Quantitative reverse transcription real-time PCR showed expression of mesenchymal markers (e.g., calponin-1, a-SMA, and collagen I), which was confirmed by FACS of the epithelial (E-cadherin-positive) and hematopoietic (CD45-negative) populations. Colocalization of epithelial and mesenchymal markers in fibrotic lung has also been shown in mouse models in which inhibition of the let-7 microRNA led to fibrosis [56] . Colocalization of SP-C and mesenchymal markers a-SMA and S100A4 was noted in approximately 40% of epithelial cells.
Evidence against epithelial-to-mesenchymal transition
Recent lineage tracing studies carried out in mouse models of kidney and liver fibrosis have failed to provide evidence of EMT, contradicting earlier studies [57] [58] [59] [60] . Of note is the report by Humphreys et al. [57] , in which perivascular fibroblasts (pericytes) were found to be the major source of myofibroblasts. Rock et al. [61 && ] reported the first lineage tracing data that were negative for EMT in lung, finding that type II alveolar epithelial cells originally expressing SP-C did not convert to a-SMA-, S100A4-or vimentin-expressing cells after bleomycin challenge. Cells expressing Scgb1a1, a marker for bronchiolar Clara cells and possibly alveolar progenitor cells, also did not convert to mesenchymal cells, nor did pericyte-like cells expressing NG2. They inferred that the majority of myofibroblasts must derive from resident stromal cells.
Resolving the discrepancy
The recent study by Rock et al. [61 && ] argues against a role for EMT as a direct source of collagen-producing (myo)fibroblasts in the lung. On the contrary, a number of other studies have shown evidence for EMT by lineage tracing or colocalization of epithelial and mesenchymal markers in human IPF lung. Several issues may account for these apparent discrepant results, some of which may also explain the widely varying results with regard to estimates of numbers of cells shown to undergo EMT in different studies: precise evaluation with confocal microscopy cannot be performed with X-gal staining, a-SMA; a smooth muscle actin; b-Gal, b-galactosidase; GFP, green fluorescent protein; TGFb1, transforming growth factor b1.
hampering colocalization, and immunodetection with anti-b-gal antibodies may be difficult, making it preferable to use a fluorescent reporter [62] ; mesenchymal markers lack specificity, so that more than one mesenchymal marker should be evaluated concurrently; resolution of immunohistochemistry and fluorescent microscopy are low and prone to artifact; confocal microscopy or evaluation of isolated cells is therefore necessary to show colocalization; changes in morphology and migration across the basement membrane have not always been examined; presence or absence argues strongly for or against EMT, respectively; the specific Cre driver used for recombination may affect results depending on extent and timing of labeling of epithelial cell populations; the bleomycin model, while the most accepted model of IPF, is flawed; results of lineage tracing may be very different in different injury/ fibrogenic models [52] ; and humans and mice likely exhibit disparate lung cell biology. Consideration should also be given to the possibility that EMT represents a spectrum of phenotypic changes in response to injury. Rather than undergoing full transition to bona fide (myo)fibroblasts, expression of mesenchymal characteristics may represent an attempt at wound repair and cell survival, as EMT has been shown to confer resistance to apoptosis [63] . These injured cells may therefore express mesenchymal markers or exhibit migratory capacity without necessarily becoming matrix-producing fibroblasts. Intrinsic to this concept would be the ability of these cells to revert back to an epithelial phenotype through the process of mesenchymal-epithelial transition. In addition, significance of EMT to the fibrogenic process may go beyond direct generation of fibroblasts and may include indirect effects related to release of cytokines by injured epithelial cells, thereby creating a profibrogenic environment (Fig. 1) .
CONCLUSION
EMT is one of several proposed mechanisms through which fibroblasts and myofibroblasts are generated. Advances have been made towards elucidating causes and mechanisms of EMT in lung fibrosis, potentially leading to new treatment options. Although human IPF studies have clearly shown colocalization of epithelial and mesenchymal markers, the number of fibroblasts arising from epithelial cells was small in some lineage tracing studies, suggesting effects of EMT beyond direct phenotypic conversion to matrix-producing cells. Two other possible implications of EMT beyond direct conversion to a fully differentiated functional fibroblast phenotype are: EMT may be part of a response to injury and an attempt to escape apoptosis and, if so, EMT may serve as a marker of epithelial injury, in which case inhibition of EMT may in fact have adverse consequences in IPF; and EMT may be involved in aberrant epithelialmesenchymal interactions, and AECs expressing mesenchymal markers may release factors that promote a fibrogenic microenvironment. Both of these hypotheses await further evaluation.
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